Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2361MR)

This product GTTS-WQ2361MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2361MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8210MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ10782MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ7263MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ1454MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ1947MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ9748MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ8560MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ10597MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY3300054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW